Table of Contents

company-logo

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Arcutis Biotherapeutics Dividend Announcement

• Arcutis Biotherapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Arcutis Biotherapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Arcutis Biotherapeutics Dividend History

Arcutis Biotherapeutics Dividend Yield

Arcutis Biotherapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Arcutis Biotherapeutics stock? Use our calculator to estimate your expected dividend yield:

Arcutis Biotherapeutics Financial Ratios

P/E ratio-6.85
PEG ratio0.07
P/B ratio8.55
ROE-119.11%
Payout ratio0.00%
Current ratio2.46
Quick ratio2.38
Cash Ratio0.78

Arcutis Biotherapeutics Dividend FAQ

Does Arcutis Biotherapeutics stock pay dividends?
Arcutis Biotherapeutics does not currently pay dividends to its shareholders.
Has Arcutis Biotherapeutics ever paid a dividend?
No, Arcutis Biotherapeutics has no a history of paying dividends to its shareholders. Arcutis Biotherapeutics is not known for its dividend payments.
Why doesn't Arcutis Biotherapeutics pay dividends?
There are several potential reasons why Arcutis Biotherapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Arcutis Biotherapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Arcutis Biotherapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Arcutis Biotherapeutics a dividend aristocrat?
Arcutis Biotherapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Arcutis Biotherapeutics a dividend king?
Arcutis Biotherapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Arcutis Biotherapeutics a dividend stock?
No, Arcutis Biotherapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Arcutis Biotherapeutics stocks?
To buy Arcutis Biotherapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Arcutis Biotherapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.